Pierre Fabre Dermatologie-Product Pipeline Review-2012 New Report
Naperville, IL -- (SBWire) -- 02/07/2013 --Pierre Fabre Medicament - Product Pipeline Review - 2012 provides data on the Pierre Fabre Medicament’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from databases, Pierre Fabre Medicament’s corporate website, SEC filings, investor presentations and featured press releases, both from Pierre Fabre Medicament and industry-specific third party sources.
- Pierre Fabre Medicament - Brief Pierre Fabre Medicament overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pierre Fabre Medicament human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pierre Fabre Medicament with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pierre Fabre Medicament’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Pierre Fabre Medicament’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pierre Fabre Medicament in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pierre Fabre Medicament’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pierre Fabre Medicament.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pierre Fabre Medicament and identify potential opportunities in those areas.
To view table of contents for this market report please visit:
Media Relations Contact
View this press release online at: http://rwire.com/203198